Research Studies for Multiple Sclerosis
This study is being done to see how effective and tolerable ublituximab is when given to people who had been receiving different anti-CD20 therapy for relapsing multiple sclerosis. Ublituximab is approved by the US Food and Drug Administration (FDA) with the name BRIUMVI®, for adults with relapsing forms of multiple sclerosis.
The investigational drug is a Bruton Tyrosine Kinase Inhibitor, a selective therapy aiming to reduce MS relapses. The trials will last up to 30 months (core study), plus a 5-year extension part. During the core study, participants will have approximately 15 study site visits, including a follow-up appointment.
You could be able to take part in these trials if you’re aged 18-55, have been diagnosed with MS (Relapsing Remitting or Secondary Progressive) and have had 1 documented relapse in the last year, or 2 in the last 2 years.
Do you have Relapsing-Remitting Multiple Sclerosis (RRMS)?
There is a new clinical trial of the investigational oral drug PIPE-307 that is being tested to see if it can help adults with RRMS.
It is believed that PIPE-307 will bind a muscarinic receptor on a specific brain cell that may potentially result in new myelin formulation (remyelination). The goal of this study is to test the safety and behavior of PIPE-307 in your body when taken daily by mouth for 6 months. The study will also test whether treatment with PIPE-307 affects your MS symptoms and how well you can function in daily life.
If you qualify, you will be in the study for up to 34 weeks and will visit the study site about 7 times. To potentially qualify, you must:
If you would like to learn more about the VISTA study, please contact the Research Department at 781-551-5812 opt. 2
See if one of our Research Studies may be a good fit for you...
Call us at 781-551-5812 or fill out the online appointment form...